Patricia Rubio-Marin

Dr. Patricia Rubio-Marin

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2023 in Circulation
Verified
Journal Article
Open access
LILeopoldo Pérez De Isla
Leopoldo Pérez De Isla
JDJose luis Díaz Díaz
Jose luis Díaz Díaz
MRManuel Jesús Romero-Jiménez
Manuel Jesús Romero-Jiménez
OMOvidio Muñiz-Grijalvo
Ovidio Muñiz-Grijalvo
JMJuan D. Mediavilla
Juan D. Mediavilla
PMPedro Mata
Pedro Mata
Background: The effect of alirocumab, a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, on coronary plaque burden in patients with familial hypercholesterolemia has not been addressed. Our aim was to assess changes in coronary plaque burden and its characteristics after treatment with alirocumab by quantification and characterization of atherosclerotic plaque throughout the coronary tree on the basis of a noninvasive analysis of coronary computed tomographic angiography in asymptomatic subjects with familial hypercholesterolemia receiving optimized and stable treatment with maximum tolerated statin dose with or without ezetimibe. Methods: This study is a phase IV, open-label, multicenter, single-arm clinical trial to assess changes in coronary plaque burden and its characteristics after 78 weeks of treatment with alirocumab in patients with familial hypercholesterolemia without clinical atherosclerotic cardiovascular disease. Participants underwent an initial coronary computed tomographic angiography at baseline and another at 78 weeks. Every patient received 150 mg of alirocumab subcutaneiously every 14 days in addition to high-intensity statin therapy. The main outcome was the change on coronary plaque burden and its characteristics by quantification and characterization of atherosclerotic plaque throughout the coronary tree on the basis of analysis of coronary computed tomographic angiography. Results: The study was completed by 104 patients. The median age was 53.3 (46.2–59.4) years. Of these patients, 54 were women (51.9%). Median low-density lipoprotein cholesterol was 138.9 (117.5–175.3) mg/dL at entry and 45.0 (36.0–65.0) mg/dL at follow-up ( P <0.001). Coronary plaque burden changed from 34.6% (32.5%–36.8%) at entry to 30.4% (27.4%–33.4%) at follow-up ( P <0.001). A significant change in the characteristics of the coronary atherosclerosis was also found: an increase in the proportion of calcified (+0.3%; P <0.001) and mainly fibrous (+6.2%; P <0.001) plaque, accompanied by a decrease in the percentage of fibro-fatty (–3.9%; P <0.001) and necrotic plaque (–0.6%; P <0.001). Conclusions: Treatment with alirocumab in addition to high-intensity statin therapy resulted in significant regression of coronary plaque burden and plaque stabilization on coronary computed tomographic angiography over 78 weeks in these groups of patients with familial hypercholesterolemia without clinical atherosclerotic cardiovascular disease. ARCHITECT (Effect of Alirocumab on Atherosclerotic Plaque Volume, Architecture and Composition) could link and explain ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) results. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05465278.

1 January 2024 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
LILeopoldo Pérez De Isla
Leopoldo Pérez De Isla
JDJose luis Díaz Díaz
Jose luis Díaz Díaz
MRManuel Jesús Romero-Jiménez
Manuel Jesús Romero-Jiménez
OMOvidio Muñiz-Grijalvo
Ovidio Muñiz-Grijalvo
JMJuan D. Mediavilla
Juan D. Mediavilla
FIfor the SAFEHEART Investigators
for the SAFEHEART Investigators
BACKGROUND: Intensive lipid-lowering therapy may induce coronary atherosclerosis regression. Nevertheless, the factors underlying the effect of lipid-lowering therapy on disease regression remain poorly characterized. Our aim was to determine which characteristics of atherosclerotic plaque are associated with a greater reduction in coronary plaque burden (PB) after treatment with alirocumab in patients with familial hypercholesterolemia. METHODS: The ARCHITECT study (Effect of Alirocumab on Atherosclerotic Plaque Volume, Architecture and Composition) is a phase IV, open-label, multicenter, single-arm clinical trial to assess the effect of the treatment with alirocumab for 78 weeks on the coronary atherosclerotic PB and its characteristics in subjects with familial hypercholesterolemia without clinical atherosclerotic cardiovascular disease. Participants underwent a coronary computed tomographic angiography at baseline and a final one at 78 weeks. Every patient received alirocumab 150 mg subcutaneously every 14 days in addition to high-intensity statin therapy. RESULTS: One hundred and four patients were enrolled. Median age was 53.3 (46.2–59.4) years and 54 were women (51.9%). The global coronary PB changed from 34.6% (32.5%–36.8%) at entry to 30.4% (27.4%–33.4%) at follow-up, which is −4.6% (−7.7% to −1.9%; P <0.001) reduction. A decrease in the percentage of unstable core (fibro-fatty+necrotic plaque; from 14.1 [7.9–22.3] to 8.0 [6.4–10.6]; −6.6%; P <0.001) was found. A greater PB (β, 0.36 [0.13–0.59]; P =0.002) and a higher proportion of unstable core (β, 0.15 [0.08–0.22]; P <0.001) were significantly related to PB regression. CONCLUSIONS: Treatment with alirocumab in addition to high-intensity statin therapy might produce a greater PB regression in patients with familial hypercholesterolemia with higher baseline PB and in those with larger unstable core. Further studies are needed to corroborate the hypothesis raised by these results. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05465278.

1 May 2018 in Endocrinología, Diabetes y Nutrición
Verified
Journal Article
Closed access
PRPatricia Rubio-Marin
Patricia Rubio-Marin
AMAlfredo Michán-Doña
Alfredo Michán-Doña
JMJuan Maraver-Delgado
Juan Maraver-Delgado
RARaquel Arroyo-Olivares
Raquel Arroyo-Olivares
RVRosalía Barrado Varea
Rosalía Barrado Varea
PMPedro Mata
Pedro Mata

25 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JMJuan Mora-Delgado
Juan Mora-Delgado
CLCristina Lojo-Cruz
Cristina Lojo-Cruz
PRPatricia Rubio-Marin
Patricia Rubio-Marin
ECEva María Menor Campos
Eva María Menor Campos
AMAlfredo Michán-Doña
Alfredo Michán-Doña
Some patients with COVID-19 have complex hypercoagulable abnormalities that are related to mortality. The optimal dosage of low molecular weight heparin in hospitalized patients with SARS-CoV-2 pneumonia is still not clear. Our objective is to evaluate the effects of adapting the dosage of low molecular weight heparin to thrombotic and bleeding risk scales in this setting. We performed a cohort, retrospective, observational, and analytical study at the Hospital Universitario of Jerez de la Frontera, with patients admitted with SARS-CoV-2 pneumonia from 1 October 2020 to 31 January 2021. They were classified according to whether they received prophylactic, intermediate, or therapeutic doses of enoxaparin. The primary endpoint was intrahospital mortality. Secondary endpoints were the need for invasive ventilation, thromboembolic events, bleeding, and the usefulness of thrombotic and bleeding scales. After binary logistic regression analysis, considering confounding variables, it was found that the use of enoxaparin at therapeutic doses was associated with lower mortality during admission compared to prophylactic and intermediate doses (RR 0.173; 95% CI, 0.038–0.8; p = 0.025). IMPROVE bleeding risk score correlated with a higher risk of minor bleeding (RR 1.263; 95% CI, 1.105–1.573; p = 0.037). In adult hospitalized patients with SARS-CoV-2 pneumonia presenting elevated D-dimer and severe proinflammatory state, therapeutic doses of enoxaparin can be considered, especially if bleeding risk is low according to the IMPROVE bleeding risk score.

24 August 2021 in Case reports
Verified
Journal Article
Open access
PDF file
VNVirginia Naranjo-Velasco
Virginia Naranjo-Velasco
MPMarta Pastor-Mena
Marta Pastor-Mena
PRPatricia Rubio-Marin
Patricia Rubio-Marin
JAJuan Carlos Anglada-Pintado
Juan Carlos Anglada-Pintado
Introducción. Las vasculitis son enfermedades graves que suelen tener un debut muy inespecífico y un diagnóstico tardío, lo que implica una alta tasa de fracaso terapéutico. Se presenta un caso de vasculitis que puede contribuir a considerar esta enfermedad como parte del diagnóstico diferencial desde las primeras etapas del proceso de atención para garantizar un abordaje integral y un inicio temprano del tratamiento, lo que reduciría la morbimortalidad asociada a estas entidades y mejoraría la tasa de éxito de los tratamientos. Presentación del caso. Mujer caucásica de 77 años que como único antecedente presentaba hipertensión arterial de dos años de evolución y quien consultó al servicio de urgencias de una institución de segundo nivel por cuadro clínico de un mes de evolución consistente en astenia, febrícula, hiporexia y pérdida de peso. La paciente fue hospitalizada para completar la historia clínica y dados los hallazgos se sospechó de una posible translocación bacteriana secundaria a una neoplasia intestinal y se inició cobertura antibiótica empírica, pero su condición seguía empeorando. Se realizaron pruebas complementarias que no arrojaron resultados concluyentes; ante la persistencia de la fiebre, la insuficiencia renal y la anemia, se realizó una biopsia de riñón que mostró vaso arterial con necrosis fibrinoide e infiltrados de polimorfonucleares asociados, claros signos de una vasculitis activa del tipo poliangeítis microscópica. Se instauró el tratamiento indicado pero la paciente tuvo una evolución desfavorable y falleció. Conclusiones. La exposición de este caso inusual contribuye a que los profesionales de la salud consideren el diagnóstico de vasculitis desde el inicio de la atención, aun cuando la sintomatología sugiere otras patologías o incluso cuando se presentan síntomas tan inespecíficos como anemia y pérdida de peso, ya que esto ayudará a establecer un diagnóstico temprano.

30 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LCLuis Castilla-Guerra
Luis Castilla-Guerra
PLPaula Luque-Linero
Paula Luque-Linero
MFMaria del Carmen Fernandez-Moreno
Maria del Carmen Fernandez-Moreno
BGBelén Gutiérrez-Gutiérrez
Belén Gutiérrez-Gutiérrez
FFFrancisco Fuentes-Jiménez
Francisco Fuentes-Jiménez
PRPatricia Rubio-Marin
Patricia Rubio-Marin
Background/Objectives: Acute mesenteric ischemia (AMI) is a time-dependent condition associated with exceptionally high in-hospital mortality, particularly among elderly and comorbid patients. Early identification of patients at high risk of death remains challenging and has important implications for clinical decision-making. The objective of this study was to derive and internally validate a prognostic score for in-hospital mortality of patients with AMI. Materials and Methods: We conducted a multicenter, observational, retrospective cohort study including patients with AMI from 10 participating hospitals. A descriptive and analytical approach was performed. A Classification and Regression Tree (CART) model was used to determine cut-off points for continuous variables and assess their association with mortality. Based on these thresholds, a univariate analysis was performed, and variables with statistical significance (p < 0.05) were incorporated into a multivariate logistic regression model. A score—the RADIAL score—was then derived from the beta coefficients. The discriminative ability of the score was evaluated using the receiver operating characteristic (ROC) curve. Results: A total of 693 patients were studied. Thee mean age was 81 years (IQR 73–86) and 54.2% were women. A history of cardiovascular disease was present in 75.3% of participants. Overall mortality was 62.4%. Most patients (74%) were managed conservatively. Significant variables in the bivariate analysis included hypotension, age > 65 years, pH < 7.3, creatinine > 1.7 mg/dL, and absence of rectal bleeding. These variables were incorporated into the multivariate model. The resulting score showed an area under the ROC curve of 0.78 (95% CI: 0.74–0.82). Conclusions: The RADIAL score demonstrated robust predictive performance and allowed the identification of three mortality-risk groups: 30–40% (low), 50–60% (intermediate), and 80% (high). This tool may support clinical decision-making in the management of patients with AMI.